Publications by authors named "Miroslav Smisek"
Article Synopsis
- - The ADAMANT trial studied AADvac1, a new vaccine targeting abnormal tau protein in Alzheimer’s disease, administered as 11 doses to patients with mild dementia over 24 months, focusing on safety, tolerability, and effectiveness.
- - A total of 196 participants were enrolled, with AADvac1 found to be safe and well tolerated, showing some adverse events but lower serious cases compared to placebo.
- - Although the vaccine stimulated a strong immune response, there were no significant improvements in cognitive function or clinical outcomes across the entire study group, indicating a need for more extensive research in specific subgroups to assess its efficacy.
Background: Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer's disease and non-Alzheimer's tauopathies. Targeting pathological tau proteins via immunotherapy is a promising strategy for disease-modifying treatment of Alzheimer's disease. Previously, we reported a 24-week phase 1 trial on the active vaccine AADvac1 against pathological tau protein; here, we present the results of a further 72 weeks of follow-up on those patients.
View Article and Find Full Text PDFBackground: Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial.
View Article and Find Full Text PDF